Understanding Novel Therapeutic Agents for Multiple Myeloma | Zendy

Joseph D Tariman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Understanding Novel Therapeutic Agents for Multiple Myeloma

Author(s) -

Joseph D Tariman

Publication year - 2003

Publication title -

clinical journal of oncology nursing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.375

H-Index - 43

eISSN - 1538-067X

pISSN - 1092-1095

DOI - 10.1188/03.cjon.521-528

Subject(s) - medicine , multiple myeloma , malignancy , bortezomib , transplantation , disease , proteasome , proteasome inhibitor , refractory (planetary science) , chemotherapy , lenalidomide , oncology , cancer research , physics , astrobiology , biology , microbiology and biotechnology

Multiple myeloma, a B cell malignancy of the plasma cells, remains incurable. Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. New therapeutic agents have shown promising clinical use in patients with relapsed or refractory multiple myeloma. This article discusses the therapeutic applications of these novel agents with a focus on immunomodulatory drugs, proteasome inhibitors, and arsenic compounds.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research